BLPH Stock Overview
A clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bellerophon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.055 |
| 52 Week High | US$0.10 |
| 52 Week Low | US$0.03 |
| Beta | 0.70 |
| 11 Month Change | 52.78% |
| 3 Month Change | 57.14% |
| 1 Year Change | 66.67% |
| 33 Year Change | -98.37% |
| 5 Year Change | -99.13% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely
Jan 06
Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size
Sep 27Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17
Aug 15Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?
Jan 18Bellerophon Therapeutics EPS misses by $0.01
Nov 05Shareholder Returns
| BLPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 48.6% | -6.5% | -1.0% |
| 1Y | 66.7% | 14.6% | 30.3% |
Return vs Industry: BLPH exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: BLPH exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| BLPH volatility | |
|---|---|
| BLPH Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BLPH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 18 | Craig Jalbert | bellerophon.com |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
Bellerophon Therapeutics, Inc. Fundamentals Summary
| BLPH fundamental statistics | |
|---|---|
| Market cap | US$464.84k |
| Earnings (TTM) | -US$9.25m |
| Revenue (TTM) | US$5.64m |
0.1x
P/S Ratio-0.1x
P/E RatioIs BLPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLPH income statement (TTM) | |
|---|---|
| Revenue | US$5.64m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.64m |
| Other Expenses | US$14.89m |
| Earnings | -US$9.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 100.00% |
| Net Profit Margin | -164.06% |
| Debt/Equity Ratio | 0% |
How did BLPH perform over the long term?
See historical performance and comparison